Analyst consensus rating
Cadrenal Therapeutics Analyst Rating: Strong Buy
CVKD is rated Strong Buy by 3 analysts with a $14.00 target. As of 2026-09-01.
Direct answer
Cadrenal Therapeutics's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $14.00.
Forecast evidence checked September 1, 2026.
Get free Cadrenal Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.75
- Average price target
- $14.00
- High price target
- $17.00
- Low price target
- $12.00
- Low target gap
- +585.7%
- Target upside
- +700%
- High target gap
- +871.4%
- Target range width
- 285.7%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cadrenal Therapeutics?
Cadrenal Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $14.00.
How far are Cadrenal Therapeutics's low and high targets from the recorded price?
The low target implies +585.7%, while the high target implies +871.4%.
How many analysts are included in Cadrenal Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Cadrenal Therapeutics's target upside or downside calculated?
The average target of $14.00 is divided by the recorded price of $1.75, then one is subtracted to produce +700%. This does not guarantee a future return.
When was Cadrenal Therapeutics's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.